Akums Drugs & Pharmaceuticals Ratios

Akums Drugs & Pharmaceuticals Ltd Ratios

The Akums Drugs & Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Akums Drugs & Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Akums Drugs & Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Akums Drugs & Pharmaceuticals Ltd (NSE: AKUMS, BSE: 544222) is currently trading at ₹527.90, with a market capitalization of ₹85.14B. As a major player in the Health technology sector and Biotechnology industry, Akums Drugs & Pharmaceuticals Ltd remains a key stock for fundamental analysis using Akums Drugs & Pharmaceuticals Ltd Ratios.

Akums Drugs & Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Akums Drugs & Pharmaceuticals Ltd P/E ratio currently stands at 21, making it one of the most tracked metrics in Akums Drugs & Pharmaceuticals Ltd Ratios.

Historically, the Akums Drugs & Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 21
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The rising Akums Drugs & Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Akums Drugs & Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.38.

Historical P/B trend:

• 2024: 2.38
• 2023: 0
• 2022: 0
• 2021: 0

Akums Drugs & Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Akums Drugs & Pharmaceuticals Ltd P/S ratio currently stands at 1.72, an important part of Akums Drugs & Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.72
• 2023: 0
• 2022: 0
• 2021: 0

The rising Akums Drugs & Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Akums Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Akums Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 15.37.

Historical Akums Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 15.37
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The rising Akums Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Akums Drugs & Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Akums Drugs & Pharmaceuticals Ltd EV currently stands at ₹66.29B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 66.29B
• 2023: 0
• 2022: 0
• 2021: 0

Akums Drugs & Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Akums Drugs & Pharmaceuticals Ltd EV/EBITDA ratio is currently 14.31, a key metric in Akums Drugs & Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 14.31
• 2023: 0
• 2022: 0
• 2021: 0

Higher Akums Drugs & Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Akums Drugs & Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Akums Drugs & Pharmaceuticals Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.03
• 2023: 0.80
• 2022: 0.86
• 2021: 0.64

Akums Drugs & Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Akums Drugs & Pharmaceuticals Ltd ROE currently stands at 18%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 18
• 2023: -0.57
• 2022: 14.17
• 2021: -33.52

Akums Drugs & Pharmaceuticals Ltd maintains stable profitability levels.

Akums Drugs & Pharmaceuticals Ltd Ratios Analysis Summary

The Akums Drugs & Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Akums Drugs & Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Akums Drugs & Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.